معرفی
Dr. R. Brad Jones is an Associate Professor at Weill Cornell Medical College with joint appointments in the Department of Microbiology and Immunology and the Division of Infectious Diseases. As Principal Investigator of the $28M NIH-funded Research Enterprise to Advance a Cure for HIV (REACH), he leads multidisciplinary research focused on developing HIV cure strategies through immunological approaches.
Education:
- Ph.D. in Immunology, University of Toronto (2011)
- B.Sc., Simon Fraser University (2004)
Research Focus: Dr. Jones' laboratory investigates cellular immune responses to HIV, with emphasis on overcoming immune evasion mechanisms. Key research areas include:
- Harnessing cytotoxic T cells and natural killer cells to eliminate HIV reservoirs
- Engineering immune cells through genetic and materials science approaches
- Developing latency reversal agents and immunotherapeutics
- Optimizing T-cell vaccine strategies against conserved viral epitopes
- Clinical translation of cure strategies through the REACH collaboratory
Publication Trends: Analysis of Dr. Jones' recent publications (2021-2025) reveals consistent focus on HIV reservoir characterization, CTL resistance mechanisms, and therapeutic interventions. Key themes include viral latency reversal using small molecules (EZH2/PTPN inhibitors), reservoir quantification technologies (ddPCR/SMRTcap), and innovative immunotherapies (autologous T-cell therapies, bNAbs). The work demonstrates increasing emphasis on multi-omics approaches and global cure implementation strategies.
Leadership & Recognition:
- Steering Committee Member, Global Scientific Strategy for HIV Cure (IAS)
- Scientific Advisory Board Member, French National Agency for AIDS Research (ANRS)
- Principal Investigator, $28M NIH REACH Collaboratory
Research Infrastructure: The Jones Lab develops advanced models including participant-derived xenografts and primary cell latency systems. Current projects focus on targeting metabolic profiles of reservoir cells, HIV integration site influences, and combinatorial immunotherapy approaches.
